Clinical Trial

miR-101-3p and Autotaxin in SLE Patients

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated November 26, 2025 (before its estimated June 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
Systemic lupus erythematosus (SLE) is a complex autoimmune disease affecting multiple organs and characterized by heterogeneous clinical manifestations. This case-control study aims to assess the association between serum expression levels of MicroRNA-101-3p and Autotaxin (ATX) in SLE patients compared with healthy controls. The hypothesis is that dysregulation of miR-101-3p and ATX contributes to SLE pathogenesis and may serve as potential non-invasive biomarkers for disease activity and prognosis.
Trial Details
NCT Number NCT07252141
Lead Sponsor Eman Mohamed Shawky
Conditions Systemic Lupus Erythematosus (SLE)
Enrollment 40 participants
Start Date 2025-12-30
Primary Completion 2026-06-30 (estimated)
Study Completion 2026-07-30 (estimated)
Updated on ClinicalTrials.gov 2025-11-26